1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
End-of-day quote Korea Stock Exchange  -  2022-06-30
179000.00 KRW   +0.28%
06/26Celltrion Wins Sales Approval Recommendation For Its CT-P16 From European Medicines Agency's Committee
RE
06/06Celltrion Eyes to Boost Market Share in Europe of Rheumatoid Arthritis Medication to 50%
MT
05/18Celltrion, Inc. authorizes a Buyback Plan.
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
175500 174500 176000 178500 179000 Last
923160 568410 410355 803073 527545 Volume
+2.33% -0.57% +0.86% +1.42% +0.28% Change
Estimated financial data (e)
Sales 2022 2 170 B 1,67 B 1,67 B
Net income 2022 587 B 0,45 B 0,45 B
Net cash position 2022 988 B 0,76 B 0,76 B
P/E ratio 2022 42,8x
Yield 2022 0,19%
Sales 2023 2 388 B 1,84 B 1,84 B
Net income 2023 704 B 0,54 B 0,54 B
Net cash position 2023 1 162 B 0,89 B 0,89 B
P/E ratio 2023 36,0x
Yield 2023 0,23%
Capitalization 24 748 B 19 031 M 19 031 M
EV / Sales 2022 11,0x
EV / Sales 2023 9,88x
Nbr of Employees 2 034
Free-Float 75,0%
More Financials
Company
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical... 
More about the company
Ratings of Celltrion, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CELLTRION, INC.
06/26Celltrion Wins Sales Approval Recommendation For Its CT-P16 From European Medicines Age..
RE
06/06Celltrion Eyes to Boost Market Share in Europe of Rheumatoid Arthritis Medication to 50..
MT
05/18Celltrion, Inc. authorizes a Buyback Plan.
CI
05/17Celltrion, Inc. announces an Equity Buyback for 500,000 shares.
CI
05/16Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/12Celltrion's Net Profit Falls 39.2% in Q1; Shares Slip 6%
MT
04/28Celltrion To Enter U.S. Humira Biosimilar Market Following Patent Agreement With AbbVie
AQ
04/19Celltrion's CT-P6 Demonstrates Equivalent Safety, Efficacy With HERCEPTIN
AQ
04/18Celltrion Healthcare Starts Selling Chronic Inflammatory Disease Biosimilar Yuflyma in ..
MT
04/07Regeneron's Disclaimer Of Aflibercept Formulation Patent Causes PTAB Denial Of Institut..
AQ
04/05Celltrion Announces Agreement With Brazilian Government To Supply Infliximab Biosimilar
AQ
04/01Regeneron Disclaims An Aflibercept Formulation Patent In Response To Celltrion PGR
AQ
03/29Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on February 21, 2022.
CI
03/25Celltrion, Inc.'s Equity Buyback announced on February 21, 2022, has expired with 507,9..
CI
03/24South Korea’s Kospi Falls on Higher Energy Costs, Geopolitical Woes; Samsung Elec..
MT
More news
News in other languages on CELLTRION, INC.
05/25MÄRKTE ASIEN/Breite Erholung - Tokio mit Konjunktursorgen etwas leichter
05/25MÄRKTE ASIEN/Freundlich - Gelegenheitskäufe nach jüngstem Rücksetzer
05/18Celltrion, Inc. autorise un plan de rachat.
05/17CELLTRION, INC. (KOSE : A068270) annonce un rachat d'actions pour 500 000 actions.
05/16Celltrion, Inc. annonce ses résultats financiers pour le premier trimestre clos le 31 m..
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 179 000,00 KRW
Average target price 198 884,14 KRW
Spread / Average Target 11,1%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-9.60%19 031
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.83%40 011
SEAGEN INC.16.50%33 154
ALNYLAM PHARMACEUTICALS, INC.-12.58%17 911